Kura Oncology(KURA) - 2024 Q3 - Quarterly Results

Financial Performance - Net loss for Q3 2024 was $54.4 million, compared to a net loss of$38.6 million in Q3 2023, indicating an increase of 41%[10] - Research and development expenses for Q3 2024 were $41.7 million, up from$29.3 million in Q3 2023, representing a 42% increase[9] - General and administrative expenses for Q3 2024 were $18.2 million, compared to$13.1 million in Q3 2023, reflecting a 39% increase[9] - As of September 30, 2024, cash, cash equivalents, and short-term investments totaled $455.3 million, up from$424.0 million as of December 31, 2023[10] - The company expects to fund current operations into 2027 based on its operating plan[11] Clinical Development - Topline results from the registration-directed trial of ziftomenib in relapsed/refractory NPM1-mutant AML are expected in early 2025[1] - The Phase 1b expansion study of ziftomenib is currently enrolling at a dose of 600 mg across all cohorts, with 45 patients already enrolled since August 2024[5] - Kura plans to initiate a proof-of-concept study for ziftomenib in advanced gastrointestinal stromal tumors (GIST) in the first half of 2025[6] - The company aims to present updated data from the KOMET-007 trial at the ASH Annual Meeting in December 2024[12] - Kura has received Breakthrough Therapy Designation for ziftomenib, which targets approximately 30% of new AML cases annually[3]